These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 19139038)

  • 1. Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.
    Shukuya T; Takahashi T; Tamiya A; Ono A; Igawa S; Tsuya A; Nakamura Y; Murakami H; Naito T; Kaira K; Endo M; Yamamoto N
    Jpn J Clin Oncol; 2009 Mar; 39(3):158-62. PubMed ID: 19139038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: a retrospective study in Japan.
    Kenmotsu H; Ohde Y; Shukuya T; Eida H; Akamatsu H; Ono A; Nakamura Y; Tsuya A; Kaira K; Naito T; Murakami H; Takahashi T; Maniwa T; Isaka M; Endo M; Kondo H; Yamamoto N
    Respir Investig; 2012 Dec; 50(4):157-61. PubMed ID: 23199980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses.
    Urushiyama H; Jo T; Yasunaga H; Michihata N; Matsui H; Hasegawa W; Takeshima H; Sakamoto Y; Hiraishi Y; Mitani A; Fushimi K; Nagase T; Yamauchi Y
    Cancer Med; 2018 Oct; 7(10):4863-4869. PubMed ID: 30151905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
    Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
    Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer.
    Hirai F; Seto T; Shimokawa M; Inamasu E; Toyozawa R; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
    Anticancer Res; 2014 Feb; 34(2):927-31. PubMed ID: 24511034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of Pharmacists in Completion of Adjuvant Cisplatin-Vinorelbine Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer].
    Morimoto Y; Takei H; Tachibana K; Nakazato Y; Tanaka R; Nagashima Y; Watanabe K; Seki R; Shinohara T; Kondo H
    Yakugaku Zasshi; 2018; 138(3):437-442. PubMed ID: 29503435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Gebbia V; Galetta D; Riccardi F; Cariello S; Gebbia N
    Br J Cancer; 1997; 76(11):1509-17. PubMed ID: 9400950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.
    Sonobe M; Okubo K; Teramukai S; Yanagihara K; Sato M; Sato T; Chen F; Sato K; Fujinaga T; Shoji T; Omasa M; Sakai H; Miyahara R; Bando T; Date H
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1199-206. PubMed ID: 25253046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
    Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Combination of cisplatin and vinorelbine as adjuvant chemotherapy in non-small cell lung cancer patients--feasibility assessment of 5 consecutively treated patients].
    Hirahara K; Tanaka J; Itoh R; Kuriyama H; Tanaka H; Kagamu H; Yoshizawa H; Gejyo F
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):109-11. PubMed ID: 18195537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
    Comella P; Frasci G; Panza N; Manzione L; Lorusso V; Di Rienzo G; Cioffi R; De Cataldis G; Maiorino L; Bilancia D; Nicolella G; Natale M; Carpagnano F; Pacilio C; De Lena M; Bianco A; Comella G
    J Clin Oncol; 1999 May; 17(5):1526-34. PubMed ID: 10334540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.
    Shukuya T; Takahashi T; Harada H; Akamatsu H; Sakaguchi C; Imai H; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi K; Yamamoto N
    Anticancer Res; 2012 Feb; 32(2):675-80. PubMed ID: 22287762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
    Martoni A; Marino A; Sperandi F; Giaquinta S; Di Fabio F; Melotti B; Guaraldi M; Palomba G; Preti P; Petralia A; Artioli F; Picece V; Farris A; Mantovani L
    Eur J Cancer; 2005 Jan; 41(1):81-92. PubMed ID: 15617993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
    Kenmotsu H; Ohde Y; Wakuda K; Nakashima K; Omori S; Ono A; Naito T; Murakami H; Kojima H; Takahashi S; Isaka M; Endo M; Takahashi T
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):609-614. PubMed ID: 28761967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Pacilio C; Gravina A; Caputi V; Botti G; Comella G
    Ann Oncol; 1997 Oct; 8(10):1045-8. PubMed ID: 9402180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid (intravenous and oral) administration of vinorelbine plus cisplatinum followed by oral vinorelbine as first-line therapy of advanced non-small cell lung cancer: a phase II study.
    Martoni AA; Melotti B; Sperandi F; Giaquinta S; Piana E; Pavesi L; Da Prada G; Lelli G
    Lung Cancer; 2008 Jun; 60(3):387-92. PubMed ID: 18160123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
    Douillard JY; Rosell R; De Lena M; Carpagnano F; Ramlau R; Gonzáles-Larriba JL; Grodzki T; Pereira JR; Le Groumellec A; Lorusso V; Clary C; Torres AJ; Dahabreh J; Souquet PJ; Astudillo J; Fournel P; Artal-Cortes A; Jassem J; Koubkova L; His P; Riggi M; Hurteloup P
    Lancet Oncol; 2006 Sep; 7(9):719-27. PubMed ID: 16945766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.
    Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt W; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Zuna I; Griesinger F; Thomas M;
    Ann Oncol; 2013 Apr; 24(4):986-92. PubMed ID: 23161898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer.
    Hisakane K; Yoh K; Nakamura N; Udagawa H; Kirita K; Umemura S; Matsumoto S; Niho S; Akimoto T; Tsuboi M; Goto K
    Medicine (Baltimore); 2017 Nov; 96(47):e8635. PubMed ID: 29381935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.